Table 2.
Prevalence of metabolic complicationsa in the cohort
| Prevalence of Complications
|
Prevalence of Treatment among Patients with Complications
|
|||
|---|---|---|---|---|
| n | % | n | % | |
| Hyperparathyroidism | 610 | 59 | 87 | 14 |
| Anemia | 210 | 20 | 37 | 18 |
| Acidosis | 160 | 15 | 35 | 22 |
| Hyperkalemia | 176 | 17 | 87 | 49 |
| Hyperphosphatemia | 84 | 8 | 32 | 38 |
a
Hyperparathyroidism was defined as a PTH >60 pg/ml or active vitamin D treatment; anemia was defined as Hb<110 g/L according to K/DOQI-based criteria or erythropoiesis-stimulating agent (ESA) treatment; acidosis was defined a tCO2 <22 mmol/L) or bicarbonate treatment; hyperkalemia was defined as plasma potassium concentration >5 mmol/L or ion exchange resin treatment; hyperphosphatemia was defined as plasma phosphate concentration >4.3 mg/dl (1.38 mmol/L) or phosphate binder treatment.